A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Study sponsor: Exelixis
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-08-19Actual
Enrollment · participants187Actual
Source updated2026-10-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.